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engue vaccine late stage development update
. Lang
Sanoﬁ Pasteur, Lyons, France
Research into developing a vaccine against dengue began more
han 60 years ago. Sanoﬁ Pasteur joined this international research
rogram in 1994 and in 2010 phase III studies of a tetravalent
engue vaccine started throughout Asia Paciﬁc and Latin America.
Sanoﬁ Pasteur’s candidate vaccine—the CYD TDV—is a recom-
inant, live, attenuated, vaccine administered subcutaneously in a
-dose, 0–6–12 month regimen. 28 000 children and adults have
eceived 31 dose of vaccine as ofMarch 2012. A pooled safety analy-
is on1728CYDTDVvaccinees, 549active controls, and490placebo
ontrolswas done from the eleven completed Phase I/II trials. Over-
ll for dengue vaccines, the proportions of subjects reporting at
east one reaction decreased after the 3 successive doses. Results
ere not affected by either ﬂavivirus immune status at inclusion or
ge at vaccination. The observed safety proﬁle of the CYD TDV can-
idate is comparable to that of licensed control vaccines. Overall
he safety proﬁle of TDV is considered as satisfactory. In a series of
hase II studies performed in endemic and non endemic countries,
7%–100% of vaccinees are seropositive (PRNT50 titre ≥10) to all
our serotypes after three doses of TDV. Moreover, the results of
-years of immunogenicity follow-up of 80 Vietnamese adults and
hildren showed a good persistence of neutralizing antibodieswith
5% of the subjects still seropositive against the 4 serotypes three
ears post dose-3, although possibly boosted by natural exposure.
The next major milestone for this much-needed vaccine against
engue disease is the availability before the end of 2012 of the ﬁrst
fﬁcacy results from a study of 4000 children aged 4–11y in Ratch-
buri, Thailand. Assuming positive results of this efﬁcacy trial, the
icensure of this vaccine in highly endemic countries is expected to
ccur within the next 2 -4 years.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.016
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otential impact of dengue vaccination: a modeling approach
. Massad
Universidade de Sao Paulo, Sao Paulo, Brazil
Dengue is a major public health concern in Brazil. Dengue
accines should help, when available, to signiﬁcantly reduce the
urden of dengue but raise a number of question around their best
se. In this context, mathematical models can provide insights onnfectious Diseases 16S (2012) e2–e157 e5
questions such as optimal age for vaccination or respective beneﬁts
of routine and catch-up vaccination at different coverage rates.
We ﬁrst present analytical results related to the optimal age for
vaccination and expected beneﬁts from catch-up campaigns using
the most recent seroprevalence data available for Brazil. We then
present the results obtained with an age-structured, host-vector
compartmental model that captures seasonality and interactions
between the four dengue serotypes. This model was adapted to
the Brazilian situation through the use of surveillance data for
age and severity-speciﬁc incidence as well as available informa-
tion on vector density and dengue seroprevalence according to age.
Both analyses lead to the conclusion that starting routine vaccina-
tion at an early age (2 years of age) provides the largest reduction
of dengue incidence per vaccine dose administered whatever the
force of infection, vaccine coverage or efﬁcacy considered. Rou-
tine vaccination alone is however expected to get a limited impact
on dengue incidence the ﬁrst year of its implementation. Com-
plementing routine vaccination by catch-up campaigns enables to
obtain very rapidly a high level of disease control if offered to a
sufﬁcient number of cohorts (e.g. children from 3 to 14 years of
age). The results of an ongoing efﬁcacy and large scale safety study
should help to reﬁne the results on the beneﬁts expected from a
dengue vaccination program.
http://dx.doi.org/10.1016/j.ijid.2012.05.017
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Roadmap for successful dengue vaccine introduction
R. Tapia-Conyer
Instituto Carlos Slim de la Salud, Mexico City, Mexico
Worldwide dengue epidemics continue to increase; climate
change, growing urbanization and migration patterns predict our
scenario. These epidemiological and sociological conditions impose
an overwhelming economic burden and use of health services due
to dengue’s high morbidity in all socioeconomically strata. Up to
now, the most commonly used control strategy against dengue has
been vector control, which has proven limited effectiveness.
Thanks to R&D efforts a safe and effective dengue vaccine could
become available in the near future. In this paramount, the coun-
tries develop preparedness plans for the introduction of a dengue
vaccine that ought to include:
- Determination of the real dengue burden of disease, by
strengthening information systems and developing speciﬁc epi-
demiological studies.
- Development of a vaccine introduction strategy: deﬁning speciﬁc
target populations, strengthening vaccine delivery platform, and
training.
- Adjustment of the regulatory requirements, to allow proper and
timely licensing of the new vaccine.
- Implementation of econometric studies to estimate costs
involved in the vaccine introduction and cost-effectiveness anal-
ysis.
- Strengthening dengue prevention and control programs.
- Ensuring budgetary resources.
